在更新该版NCCN乳腺癌指南之前,采用以下检索词进行电子检索获取乳腺癌关键文献:乳腺癌、乳腺肿瘤、导管原位癌、炎性乳腺癌、或叶状乳腺癌。 Prior to the updateof this version of the NCCN Guidelines for Breast Cancer, an electronic search of the PubMed database was performed to obtain key literaturein B...
high-risk breast cancer (see eligibility criteria listed on BINV-K). In patients eligible for both adjuvant olaparib and abemaciclib, the optimal choice of therapy and sequencing is not known. (Also for BINV-8)
Imaging, 3rd bullet added:For patients with germline mutations or family history of breast cancer, please refer to See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 新增:治疗后监测 Added:Post treatment monitoring 新增...
Replaced No clinical benefit after 3 sequential lines of targeted therapy or ECOG performance status ≥3 with Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks ...
基于 ASCENT 研究中 SG 展现的健康相关生活质量(HRQoL)的显著改善结果,2024 年更新的 ESMO 转移性乳腺癌在线指南 v. 1.1 版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)[3]将 SG 治疗 mTNBC 的 ESMO 临床获益量表(ESMO-MCBS)评分,由既往的 4 分调整为最高等级 5 分,这也是目前 mTNBC 二线...
[5]Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. | Journal of Clinical Oncology ...
cancer care options likely to have the best results 9 Based on treatment guidelines used by health care providers worldwide 9 Designed to help you discuss cancer treatment with your doctors NCCN Guidelines for Patients® Metastatic Breast Cancer, 2022 1 Metastatic Breast Cancer National Comprehensive...
Reference 2 added: Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070. 原文共享 相关链接 晚期三阴性乳腺癌患者一线治疗新方案 晚期乳腺癌芳香酶抑制剂耐药后新方案 ...
NCCNGuid lin fo P i n ™Version2010BreastCaNCerAlsoavailableatNCCNMadepossiblebyagenerouscharitablecontributionfromSusanG.KomenfortheCure®2BreastCaNCerTableo ContentsMapo theNCCNMemberInstitutions...3AbouttheNCCNGuidelines orPatients™...
* Modified footnote "o" for consistency with NCCN Guidelines for Breast Cancer Risk Reduction. The footnote states "CYP2D6 genotype testing is not recommended in women who are considering tamoxifen." *为了与NCCN降低乳腺癌风险指南一致修改脚注“o”。脚注指出“在考虑他莫昔芬的女性中不建议CYP2D6基因...